A prospective study of pain control by a 2-step irradiance schedule during topical photodynamic therapy of nonmelanoma skin cancer

Dermatologic Surgery

Volumn 40, Issue 12, 2014, Pages 1390-1394

  Zeitouni, Nathalie C ^a   Sunar, Ulas ^b   Rohrbach, Daniel J ^b   Paquette, Anne D ^b   Bellnier, David A ^b   Shi, Yi ^b   Wilding, Gregory ^b   Foster, Thomas H ^c   Henderson, Barbara W ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; METHYL 5-AMINOLEVULINATE; PHOTOSENSITIZING AGENT;

ADULT; AGED; ANALGESIA; ARTICLE; BASAL CELL CARCINOMA; CAUCASIAN; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; HYPOPIGMENTATION; LASER; LIGHT; LIGHT EMITTING DIODE; LIGHT IRRADIANCE; MALE; NON MELANOMA SKIN CANCER; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PHOTODYNAMIC THERAPY; PROSPECTIVE STUDY; TREATMENT RESPONSE; VISUAL ANALOG SCALE; ANALOGS AND DERIVATIVES; CARCINOMA, BASAL CELL; MIDDLE AGED; PAIN MEASUREMENT; PHOTOCHEMOTHERAPY; PROCEDURES; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; AMINOLEVULINIC ACID; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MANAGEMENT; PAIN MEASUREMENT; PAIN THRESHOLD; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84916624349     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1097/DSS.0000000000000183     Document Type: Article

References (28)

1. Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008;159:1245-66.
2. Lee Y, Baron ED. Photodynamic therapy: current evidence and applications in dermatology. Semin Cutan Med Surg 2011;30:199-209.
3. Dirschka T, Radny P, Dominicus R, Mensing H, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol 2012;166:137-46.
4. Warren CB, Karai LJ, Vidimos A, Maytin EV. Pain associated with aminolevulinic acid-photodynamic therapy of skin disease. J Am Acad Dermatol 2009;61:1033-43.
5. Steinbauer JM, Schreml S, Babilas P, Zeman F, et al. Topical photodynamic therapy with porphyrin precursors-assessment of treatment-associated pain in a retrospective study. Photochem Photobiol Sci 2009;8:1111-6.
6. Valentine RM, Ibbotson SH, Brown CT, Wood K, et al. A quantitative comparison of 5-aminolaevulinic acid- and methyl aminolevulinate-induced fluorescence, photobleaching and pain during photodynamic therapy. Photochem Photobiol 2011;87:242-9.
7. Attili SK, Dawe R, Ibbotson S. A review of pain experienced during topical photodynamic therapy-our experience in Dundee. Photodiagnosis Photodyn Ther 2011;8:53-7.
8. Ibbotson SH, Valentine R, Hearn R. Is the pain of topical photodynamic therapy with methyl aminoleuvulinate any different from that with 5-aminolaevulinic acid? Photodermatol Photoimmunol Photomed 2012;5:272-3.
9. Holmes MV, Dawe RS, Ferguson J, Ibbotson HS. A randomized, double-blind, placebo-controlled study of the efficacy of tetracaine gel (Ametop) for pain relief during topical photodynamic therapy. Br J Dermatol 2004;150:337-40.
10. von FV, Hoffmann G, Hoff-Lesch S, Abuzahra F, et al. Photodynamic therapy of multiple actinic keratoses: reduced pain through use of visible light plus water-filtered infrared A compared with light from light-emitting diodes. Br J Dermatol 2010;163:607-15.
11. Cottrell WJ, Paquette AD, Keymel KR, Foster TH, et al. Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. Clin Cancer Res 2008;14:4475-83.
12. Zeitouni NC, Paquette AD, Housel JP, Shi Y, et al. A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. Lasers Surg Med 2013;45:89-94.
13. Wiegell SR, Skiveren J, Philipsen PA, Wulf HC. Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate. Br J Dermatol 2008;158:727-33.
14. Grapengiesser S, Ericson M, Gudmundsson F, Larkö O, et al. Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002;27:493-7.
15. Arits AH, van de Weert MM, Nelemans PJ, Kelleners-Smeets NW. Pain during topical photodynamic therapy: uncomfortable and unpredictable. J Eur Acad Dermatol Venereol 2010;24:1452-7.
16. Gholam P, Weberschock T, Denk K, Enk A. Treatment with 5-aminolaevulinic acid methylester is less painful than treatment with 5-aminolaevulinic acid nanoemulsion in topical photodynamic therapy for actinic keratosis. Dermatology 2011;222:358-62.
17. Foster TH, Murant RS, Bryant RG, Knox RS, et al. Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res 1991;126:296-303.
18. Henderson BW, Busch TM, Vaughan LA, Frawley NP, et al. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res 2000;60:525-9.
19. Langmack K, Mehta R, Twyman P, Norris P. Topical photodynamic therapy at low fluence rates-theory and practice. J Photochem Photobiol B 2001;60:37-43.
20. Ericson MB, Sandberg C, Stenquist B, Gudmundson F, et al. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome. Br J Cancer 2004;151:1204-12.
21. Stebbins WG, Hanke CW. MAL-PDT for difficult to treat nonmelanoma skin cancer. Dermatol Ther 2011;24:82-93.
22. Wang I, Bendsoe N, Klinteberg CA, Enejder AM, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001;144:832-40.
23. Basset-Seguin N, Ibbotson SH, Emtestam L, Tarstedt M, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008;18:547-53.
24. Pauwels C, Mazereeuw-Hautier J, Basset-Seguin N, Livideanu C, et al. Topical methyl aminolevulinate photodynamic therapy for management of basal cell carcinomas in patients with basal cell nevus syndrome improves patient's satisfaction and reduces the need for surgical procedures. J Eur Acad Dermatol Venereol 2011;25:861-4.
25. Oseroff AR, Shieh S, Frawley NP, Cheney R, et al. Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy. Arch Dermatol 2005;141:60-7.
26. Aguilar M, de TM, Martin L, Benitez N, et al. A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities. J Eur Acad Dermatol Venereol 2010;24:1431-6.
27. Annemans L, Caekelbergh K, Roelandts R, Boonen H, et al. Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma. Eur J Dermatol 2008;18:539-46.
28. Caekelbergh K, Nikkels AF, Leroy B, Verhaeghe E, et al. Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes. J Drugs Dermatol 2009;8:992-6.